| Nov 7 |
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 7 |
PTC Therapeutics: Q3 Earnings Snapshot
|
| Nov 7 |
PTC Therapeutics GAAP EPS of -$1.39 beats by $0.13, revenue of $196.78M beats by $24.98M
|
| Nov 7 |
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
|
| Nov 6 |
PTC Therapeutics Q3 2024 Earnings Preview
|
| Nov 6 |
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
|
| Nov 1 |
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
|
| Oct 30 |
PTC Therapeutics resubmitted NDA for Translarna accepted by FDA
|
| Oct 30 |
PTC Therapeutics (NASDAQ:PTCT) grows 8.1% this week, taking one-year gains to 127%
|
| Oct 30 |
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
|
